MedTrace Logo

Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

NCT05164120 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to assess the safety, tolerability and treatment effect of the orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild to moderate COVID-19 and to generate proof of concept for future trials.

Conditions

Interventions

DRUG

Belnacasan

Oral administration

DRUG

Placebo

Tablet containing 0mg of API

Sponsors & Collaborators

  • MedStar Health

    lead OTHER

Principal Investigators

  • Glenn Wortmann, MD · MedStar Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2022-07-18
Completion
2022-10-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05164120 on ClinicalTrials.gov